Manchester Buprenorphine Doctors

Feature Your Practice at the Top of This City Page

Locate Manchester buprenorphine and suboxone doctors who specialize in the treatment of opioid addiction.

Dr. William J Kassler, M.D.

Manchester Community Health Center

145 Hollis Street

Manchester, NH 03101

Main Tel: (603) 626-9500

Dr. Roland Andre Lavallee, M.D.

Farnum Center

140 Queen City Avenue

Manchester, NH 03101

Main Tel: (603) 622-3020

Dr. Robert E. Feder, M.D.

753 Chestnut Street

Manchester, NH 03104

Main Tel: (603) 860-2593

Dr. Richard Clyde Tomb, M.D.

148 Coolidge Avenue

Manchester, NH 03102

Main Tel: (603) 689-7890

Dr. Sreenivas Katragadda, M.D.

148 Coolidge Street

Manchester, NH 03104

Main Tel: (603) 883-0005

Dr. Thor Agustsson, D.O.

148 Coolidge Ave

Manchester, NH 03102

Main Tel: (603) 627-3111

Dr. Shahzeb Afsar Khan, M.D.

ELLIOT HOSPITAL

One Elliot Way

Manchester, NH 03103

Main Tel: (603) 663-2710

Dr. Michael K. Imura, M.D.

718 Smyth Road

Manchester, NH 03104

Main Tel: (603) 624-4366×6465

Dr. Laura Gayle Hancock, D.O.

718 Smyth Road

Manchester, NH 03104

Main Tel: (603) 624-4366

Dr. Gerard Joseph Hevern, M.D.

185 Queen City Avenue

Manchester, NH 03101

Main Tel: (603) 663-6730

Dr. Maria Rubio, M.D.

575 S Willow St

Manchester, NH 03103

Main Tel: (786) 232-5330

Dr. Howard Lee Suls, M.D.

601 Riverway Place

Unit 6

Bedford, NH 03110

Main Tel: (603) 622-2112

Dr. John R. Jacobs, M.D.

1160 Hooksett Road F7

Hooksett, NH 03106

Main Tel: (603) 627-5539

The Drug Treatment Act of 2000 permitted doctors who meet certain training qualifications to prescribe buprenorphine in the treatment of heroin addiction and other opioid addictions. Buprenorphine physicians became able to assist opioid addicted patients in an office setting bypassing the restrictions that typically apply to patients receiving methadone. This treatment method maximized patient convenience and accessibility thus increasing the number of people who could access medication-assisted treatment (MAT) for opioid addiction.

Buprenorphine is the medication ingredient in Suboxone, Subutex, Zubsolv, Bunavail, and Probuphine that specifically targets opioid withdrawal. Buprenorphine, or "Bup", is the leading pharmaceutical treatment (alongside methadone) for addressing opioid addiction. Both medications are in widescale use throughout the world due to their efficacy in removing the persistent discomfort associated with withdrawal from opiates (ex. runny nose, body ache, anxiety, nausea, diarrhea and other symptoms).

Buprenorphine.US is an information resource for people in search of doctors who specialize in treating opioid addiction with buprenorphine. In recent years, individuals from all age groups and backgrounds have suffered with an unexpected opioid dependency that negatively affected their family relationships, job, finances, and self-esteem. Addiction is a relentless illness, and persistent opiate withdrawal is a particularly difficult medical dilemma. There are presently thousands of U.S. physicians seeking to assist patients ready to address their opioid addiction. Buprenorphine.US is a tool for connecting buprenorphine doctors with new prospective patients wanting specialized primary care for their addictive disorder.

Buprenorphine Shown Safe and Effective in Reducing Opioid Use

A scholarly article published in The American Journal of Psychiatry found that buprenorphine was “noninferior” in elimiating opioid misuse as compared with methadone dosing. Noninferior is another way of saying reasonably similar in effectiveness.

The study was based on 272 patients meeting diagnostic criteria for Opioid Use Disorder, and was conducted over a 24 week period at 7 Canadian hospitals and community treatment clinics.

While the study did not differentiate between dependency severity levels or a patient’s years in active addiction, it did generally establish that buprenorphine was as effective in preventing opioid misuse when compared with a group of patients receiving methadone.

Progress and stabilization were primarily based on drug-testing urinalysis results although other factors were taken into consideration such as retention in opioid treatment for a longer duration of time.

Mounting evidence regarding buprenorphine safety and its overall therapeutic benefit will help to drive increases in funding for additional opioid treatment clinics and easier medication access for prospective patients desiring addiction recovery.

Opioid Use Disorder and Medication Assistance

Nearly every U.S. family is affected by addiction with opioid use disorder rising significantly in the last 10 years. Despite this trend, a surprising number of individuals still do not have access to medication-assisted therapy.

Buprenorphine based medications enjoy a proven track record of success in helping patients achieve long lasting stablization and elimination of their opioid withdrawal symptoms. A study recently published in the International Journal of Drug Policy found that almost 87% of those with opioid use disorder were not yet receiving therapeutic medications that could increase their likelihood of a successful recovery.

The good news is that there has been a substantial increase nationwide in the number of treatment providers who offer buprenorphine and counseling services. Organizations like BrightView and Acadia are opening clinics in multiple states and aim to expand their service availability in the year ahead.

With opioids now vulnerable to being adulterated with deadly fentanyl and other substances, it is important that people struggling with opioid use disorder (OUD) find treatment and support as soon as possible.

Buprenorphine based medications and methadone are making a real difference in restoring quality of life, and enabling patients to become once again fully productive, and able to focus on a healthy lifestyle. Medication assistance is key, and for many people opens a door that was previously closed for a very long time.